Figure 6 | Laboratory Investigation

Figure 6

From: H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway

Figure 6

Measurement of the number of γ-GT-positive ducts in liver sections from rats that (immediately after BDL) were treated with NaCl, RAMH, thioperamide maleate (H3R antagonist) or histamine in the absence or presence of thioperamide maleate for 1 week. In BDL rats, chronic RAMH administration induced a decrease in the number of γ-GT-positive ducts compared to NaCl-treated rats. Administration of histamine to BDL rats significantly decreased the number of γ-GT-positive ducts compared to BDL rats treated with NaCl; however, the decrease in the number of γ-GT-positive ducts (by histamine administration alone) was less than that observed in BDL rats treated with RAMH (arrows). Histamine inhibition of the number of γ-GT-positive ducts was partly blocked by thioperamide maleate; however, in the BDL rats treated with histamine+thioperamide maleate, the number of γ-GT-positive ducts was still significantly lower than that of BDL rats treated with NaCl. In BDL rats treated with thioperamide maleate, the number of γ-GT-positive ducts was slightly higher (although not significant) than that of BDL rats. Data are mean±s.e.m. of 16 cumulative values from 10 randomly selected portal areas. *P<0.05 vs corresponding value from BDL rats treated with NaCl. #P<0.05 vs corresponding value from BDL rats treated with RAMH.

Back to article page